Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shoulder InnovationsFRA:VB3 +2.86%18 EV-to-EBITDA is -8.08 as of Jul. 23, 2026. GuruFocus rates FRA:VB3 with a GF Score™ of 18/100. The stock has 3 warning signs investors should review. Among 510 Medical Devices & Instruments companies, Shoulder Innovations ranks worse than 196078.24% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Shoulder Innovations's enterprise value is €287.35 Mil.
Shoulder Innovations's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was €-35.58 Mil. Therefore, Shoulder Innovations's EV-to-EBITDA for today is -8.08.
The historical rank and industry rank for Shoulder Innovations's EV-to-EBITDA or its related term are showing as below:
FRA:VB3'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -10.52 Med: -5.03 Max: -0.86
Current: -7.93
During the past 3 years, the highest EV-to-EBITDA of Shoulder Innovations was -0.86. The lowest was -10.52. And the median was -5.03.
FRA:VB3's EV-to-EBITDA is ranked worse than 100% of 510
companies
in the Medical Devices & Instruments industry
Industry Median: 14.08
vs FRA:VB3: -7.93
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Shoulder Innovations's PE Ratio (TTM) for today is calculated as:
Shoulder Innovations's share price for today is €18.00.
Shoulder Innovations's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2.048.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Shoulder Innovations's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:VB3 vs MOBI, DCTH, VMD: EV-to-EBITDA Comparison
For the Medical Devices subindustry, Shoulder Innovations's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shoulder Innovations EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Shoulder Innovations's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Shoulder Innovations's EV-to-EBITDA falls into.
Shoulder Innovations's current Enterprise Value is €287.35 Mil.
Shoulder Innovations's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-35.58 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shoulder Innovations (FRA:VB3) has a EV-to-EBITDA of -8.08 as of Jul. 23, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Shoulder Innovations. According to the industry distribution chart, Shoulder Innovations ranks #999999 out of 510 companies in the Medical Devices & Instruments industry.
Is Shoulder Innovations' EV-to-EBITDA too high?
Shoulder Innovations' current EV-to-EBITDA is -8.08. Based on the distribution chart, Shoulder Innovations ranks #999999 out of 510 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Shoulder Innovations has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Shoulder Innovations' EV-to-EBITDA compare to MOBI and DCTH?
According to the Medical Devices & Instruments industry distribution chart, Shoulder Innovations ranks #999999 out of 510 companies for EV-to-EBITDA. This places Shoulder Innovations in the lower half of its industry. The industry median EV-to-EBITDA is 14.08. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.08, based on 510 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Shoulder Innovations. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shoulder Innovations's current EV-to-EBITDA is -8.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shoulder Innovations stock overvalued right now?
Shoulder Innovations (FRA:VB3) has a current EV-to-EBITDA of -8.08. The current EV-to-EBITDA is -8.08. Shoulder Innovations' overall GF Score™ is 18/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Shoulder Innovations (FRA:VB3), the current EV-to-EBITDA is -8.08 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Shoulder Innovations Inc is a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market. It currently offers advanced implant systems for shoulder arthroplasty. Its products include: InSet Total Shoulder Arthroplasty; InSet Reverse Shoulder Arthroplasty; ProVoyance Shoulder Planning Software; and InSet Tray System. Geographically, the company operates in United States and are planning to expand.
18GF Score
Get the complete analysis for FRA:VB3
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:VB3 has been successfully added to your 
